nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—CYP1A2—Sorafenib—liver cancer	0.176	0.316	CbGbCtD
Cyclobenzaprine—CYP2D6—Sorafenib—liver cancer	0.145	0.26	CbGbCtD
Cyclobenzaprine—CYP3A4—Sorafenib—liver cancer	0.0921	0.166	CbGbCtD
Cyclobenzaprine—CYP2D6—Doxorubicin—liver cancer	0.0879	0.158	CbGbCtD
Cyclobenzaprine—CYP3A4—Doxorubicin—liver cancer	0.0559	0.1	CbGbCtD
Cyclobenzaprine—Gynaecomastia—Sorafenib—liver cancer	0.00501	0.019	CcSEcCtD
Cyclobenzaprine—Hepatic function abnormal—Sorafenib—liver cancer	0.00465	0.0177	CcSEcCtD
Cyclobenzaprine—Gastritis—Sorafenib—liver cancer	0.00359	0.0137	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Sorafenib—liver cancer	0.00323	0.0123	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Sorafenib—liver cancer	0.00309	0.0117	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Sorafenib—liver cancer	0.00307	0.0117	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Sorafenib—liver cancer	0.00307	0.0117	CcSEcCtD
Cyclobenzaprine—Bone marrow depression—Epirubicin—liver cancer	0.00306	0.0116	CcSEcCtD
Cyclobenzaprine—Stomatitis—Sorafenib—liver cancer	0.00305	0.0116	CcSEcCtD
Cyclobenzaprine—Jaundice—Sorafenib—liver cancer	0.00305	0.0116	CcSEcCtD
Cyclobenzaprine—Bone marrow depression—Doxorubicin—liver cancer	0.00283	0.0108	CcSEcCtD
Cyclobenzaprine—Tinnitus—Sorafenib—liver cancer	0.00262	0.00995	CcSEcCtD
Cyclobenzaprine—Ageusia—Epirubicin—liver cancer	0.00255	0.00969	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Sorafenib—liver cancer	0.00251	0.00953	CcSEcCtD
Cyclobenzaprine—Alopecia—Sorafenib—liver cancer	0.00248	0.00943	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Sorafenib—liver cancer	0.00239	0.0091	CcSEcCtD
Cyclobenzaprine—Ageusia—Doxorubicin—liver cancer	0.00236	0.00897	CcSEcCtD
Cyclobenzaprine—Thinking abnormal—Epirubicin—liver cancer	0.00226	0.00858	CcSEcCtD
Cyclobenzaprine—Angioedema—Sorafenib—liver cancer	0.00223	0.00849	CcSEcCtD
Cyclobenzaprine—Syncope—Sorafenib—liver cancer	0.00219	0.00833	CcSEcCtD
Cyclobenzaprine—Leukopenia—Sorafenib—liver cancer	0.00219	0.00832	CcSEcCtD
Cyclobenzaprine—Dysarthria—Epirubicin—liver cancer	0.00219	0.0083	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Sorafenib—liver cancer	0.00215	0.00817	CcSEcCtD
Cyclobenzaprine—Atrioventricular block—Epirubicin—liver cancer	0.00213	0.0081	CcSEcCtD
Cyclobenzaprine—Gait disturbance—Epirubicin—liver cancer	0.00212	0.00805	CcSEcCtD
Cyclobenzaprine—Hypertension—Sorafenib—liver cancer	0.00211	0.00802	CcSEcCtD
Cyclobenzaprine—Coordination abnormal—Epirubicin—liver cancer	0.00211	0.008	CcSEcCtD
Cyclobenzaprine—Thinking abnormal—Doxorubicin—liver cancer	0.00209	0.00794	CcSEcCtD
Cyclobenzaprine—Myalgia—Sorafenib—liver cancer	0.00208	0.00791	CcSEcCtD
Cyclobenzaprine—Dry mouth—Sorafenib—liver cancer	0.00204	0.00774	CcSEcCtD
Cyclobenzaprine—Dysarthria—Doxorubicin—liver cancer	0.00202	0.00768	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Sorafenib—liver cancer	0.002	0.00758	CcSEcCtD
Cyclobenzaprine—Atrioventricular block—Doxorubicin—liver cancer	0.00197	0.00749	CcSEcCtD
Cyclobenzaprine—Shock—Sorafenib—liver cancer	0.00196	0.00746	CcSEcCtD
Cyclobenzaprine—Gait disturbance—Doxorubicin—liver cancer	0.00196	0.00745	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Sorafenib—liver cancer	0.00195	0.00742	CcSEcCtD
Cyclobenzaprine—Coordination abnormal—Doxorubicin—liver cancer	0.00195	0.0074	CcSEcCtD
Cyclobenzaprine—Anorexia—Sorafenib—liver cancer	0.0019	0.00723	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00182	0.00691	CcSEcCtD
Cyclobenzaprine—Hypertonia—Epirubicin—liver cancer	0.00181	0.00688	CcSEcCtD
Cyclobenzaprine—Mental disability—Epirubicin—liver cancer	0.00179	0.00682	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Sorafenib—liver cancer	0.00178	0.00676	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Sorafenib—liver cancer	0.00176	0.00667	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Sorafenib—liver cancer	0.00174	0.00659	CcSEcCtD
Cyclobenzaprine—Fatigue—Sorafenib—liver cancer	0.00172	0.00654	CcSEcCtD
Cyclobenzaprine—Hepatic function abnormal—Epirubicin—liver cancer	0.00172	0.00652	CcSEcCtD
Cyclobenzaprine—Constipation—Sorafenib—liver cancer	0.00171	0.00648	CcSEcCtD
Cyclobenzaprine—Vascular purpura—Epirubicin—liver cancer	0.00168	0.00637	CcSEcCtD
Cyclobenzaprine—Hypertonia—Doxorubicin—liver cancer	0.00168	0.00637	CcSEcCtD
Cyclobenzaprine—Mental disability—Doxorubicin—liver cancer	0.00166	0.00631	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Sorafenib—liver cancer	0.00163	0.0062	CcSEcCtD
Cyclobenzaprine—Hepatic function abnormal—Doxorubicin—liver cancer	0.00159	0.00604	CcSEcCtD
Cyclobenzaprine—Urticaria—Sorafenib—liver cancer	0.00159	0.00602	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Sorafenib—liver cancer	0.00158	0.00599	CcSEcCtD
Cyclobenzaprine—Purpura—Epirubicin—liver cancer	0.00156	0.00592	CcSEcCtD
Cyclobenzaprine—Vascular purpura—Doxorubicin—liver cancer	0.00155	0.0059	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Epirubicin—liver cancer	0.00153	0.00582	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Epirubicin—liver cancer	0.0015	0.0057	CcSEcCtD
Cyclobenzaprine—Diplopia—Epirubicin—liver cancer	0.0015	0.0057	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Sorafenib—liver cancer	0.00147	0.00559	CcSEcCtD
Cyclobenzaprine—Face oedema—Epirubicin—liver cancer	0.00145	0.0055	CcSEcCtD
Cyclobenzaprine—Purpura—Doxorubicin—liver cancer	0.00144	0.00547	CcSEcCtD
Cyclobenzaprine—Asthenia—Sorafenib—liver cancer	0.00143	0.00544	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00142	0.00538	CcSEcCtD
Cyclobenzaprine—Pruritus—Sorafenib—liver cancer	0.00141	0.00536	CcSEcCtD
Cyclobenzaprine—Ataxia—Epirubicin—liver cancer	0.00141	0.00536	CcSEcCtD
Cyclobenzaprine—Diplopia—Doxorubicin—liver cancer	0.00139	0.00528	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Doxorubicin—liver cancer	0.00139	0.00528	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Sorafenib—liver cancer	0.00137	0.00519	CcSEcCtD
Cyclobenzaprine—Face oedema—Doxorubicin—liver cancer	0.00134	0.00509	CcSEcCtD
Cyclobenzaprine—Gastritis—Epirubicin—liver cancer	0.00133	0.00505	CcSEcCtD
Cyclobenzaprine—Dizziness—Sorafenib—liver cancer	0.00132	0.00501	CcSEcCtD
Cyclobenzaprine—Ataxia—Doxorubicin—liver cancer	0.00131	0.00496	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Epirubicin—liver cancer	0.00128	0.00488	CcSEcCtD
Cyclobenzaprine—Vomiting—Sorafenib—liver cancer	0.00127	0.00482	CcSEcCtD
Cyclobenzaprine—Rash—Sorafenib—liver cancer	0.00126	0.00478	CcSEcCtD
Cyclobenzaprine—Dermatitis—Sorafenib—liver cancer	0.00126	0.00478	CcSEcCtD
Cyclobenzaprine—Headache—Sorafenib—liver cancer	0.00125	0.00475	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Epirubicin—liver cancer	0.00123	0.00468	CcSEcCtD
Cyclobenzaprine—Gastritis—Doxorubicin—liver cancer	0.00123	0.00467	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Epirubicin—liver cancer	0.00121	0.00458	CcSEcCtD
Cyclobenzaprine—Pollakiuria—Epirubicin—liver cancer	0.0012	0.00455	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Doxorubicin—liver cancer	0.00119	0.00451	CcSEcCtD
Cyclobenzaprine—Nausea—Sorafenib—liver cancer	0.00119	0.0045	CcSEcCtD
Cyclobenzaprine—Weight increased—Epirubicin—liver cancer	0.00118	0.00448	CcSEcCtD
Cyclobenzaprine—Drowsiness—Epirubicin—liver cancer	0.00116	0.00439	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Doxorubicin—liver cancer	0.00114	0.00433	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Epirubicin—liver cancer	0.00113	0.00431	CcSEcCtD
Cyclobenzaprine—Stomatitis—Epirubicin—liver cancer	0.00113	0.00428	CcSEcCtD
Cyclobenzaprine—Jaundice—Epirubicin—liver cancer	0.00113	0.00428	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00112	0.00424	CcSEcCtD
Cyclobenzaprine—Sweating—Epirubicin—liver cancer	0.00111	0.00421	CcSEcCtD
Cyclobenzaprine—Pollakiuria—Doxorubicin—liver cancer	0.00111	0.00421	CcSEcCtD
Cyclobenzaprine—Weight increased—Doxorubicin—liver cancer	0.00109	0.00415	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Epirubicin—liver cancer	0.00108	0.0041	CcSEcCtD
Cyclobenzaprine—Drowsiness—Doxorubicin—liver cancer	0.00107	0.00407	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Doxorubicin—liver cancer	0.00105	0.00398	CcSEcCtD
Cyclobenzaprine—Jaundice—Doxorubicin—liver cancer	0.00104	0.00396	CcSEcCtD
Cyclobenzaprine—Stomatitis—Doxorubicin—liver cancer	0.00104	0.00396	CcSEcCtD
Cyclobenzaprine—Hepatitis—Epirubicin—liver cancer	0.00104	0.00394	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Epirubicin—liver cancer	0.00103	0.00392	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Epirubicin—liver cancer	0.00103	0.00391	CcSEcCtD
Cyclobenzaprine—Sweating—Doxorubicin—liver cancer	0.00103	0.0039	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Doxorubicin—liver cancer	0.000999	0.00379	CcSEcCtD
Cyclobenzaprine—Tinnitus—Epirubicin—liver cancer	0.000968	0.00368	CcSEcCtD
Cyclobenzaprine—Hepatitis—Doxorubicin—liver cancer	0.000961	0.00365	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Doxorubicin—liver cancer	0.000956	0.00363	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Doxorubicin—liver cancer	0.000953	0.00362	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Epirubicin—liver cancer	0.000928	0.00352	CcSEcCtD
Cyclobenzaprine—Alopecia—Epirubicin—liver cancer	0.000917	0.00349	CcSEcCtD
Cyclobenzaprine—Tinnitus—Doxorubicin—liver cancer	0.000896	0.0034	CcSEcCtD
Cyclobenzaprine—Flatulence—Epirubicin—liver cancer	0.000891	0.00338	CcSEcCtD
Cyclobenzaprine—Tension—Epirubicin—liver cancer	0.000887	0.00337	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Epirubicin—liver cancer	0.000885	0.00336	CcSEcCtD
Cyclobenzaprine—Nervousness—Epirubicin—liver cancer	0.000878	0.00333	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Doxorubicin—liver cancer	0.000858	0.00326	CcSEcCtD
Cyclobenzaprine—Vision blurred—Epirubicin—liver cancer	0.000852	0.00324	CcSEcCtD
Cyclobenzaprine—Alopecia—Doxorubicin—liver cancer	0.000849	0.00322	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Epirubicin—liver cancer	0.000839	0.00319	CcSEcCtD
Cyclobenzaprine—Agitation—Epirubicin—liver cancer	0.000831	0.00316	CcSEcCtD
Cyclobenzaprine—Flatulence—Doxorubicin—liver cancer	0.000824	0.00313	CcSEcCtD
Cyclobenzaprine—Tension—Doxorubicin—liver cancer	0.000821	0.00312	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Doxorubicin—liver cancer	0.000819	0.00311	CcSEcCtD
Cyclobenzaprine—Malaise—Epirubicin—liver cancer	0.000815	0.0031	CcSEcCtD
Cyclobenzaprine—Nervousness—Doxorubicin—liver cancer	0.000812	0.00309	CcSEcCtD
Cyclobenzaprine—Vertigo—Epirubicin—liver cancer	0.000812	0.00308	CcSEcCtD
Cyclobenzaprine—Syncope—Epirubicin—liver cancer	0.000811	0.00308	CcSEcCtD
Cyclobenzaprine—Leukopenia—Epirubicin—liver cancer	0.000809	0.00307	CcSEcCtD
Cyclobenzaprine—Palpitations—Epirubicin—liver cancer	0.000799	0.00303	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Epirubicin—liver cancer	0.000794	0.00302	CcSEcCtD
Cyclobenzaprine—Vision blurred—Doxorubicin—liver cancer	0.000788	0.00299	CcSEcCtD
Cyclobenzaprine—Convulsion—Epirubicin—liver cancer	0.000783	0.00297	CcSEcCtD
Cyclobenzaprine—Hypertension—Epirubicin—liver cancer	0.00078	0.00296	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Doxorubicin—liver cancer	0.000776	0.00295	CcSEcCtD
Cyclobenzaprine—Myalgia—Epirubicin—liver cancer	0.000769	0.00292	CcSEcCtD
Cyclobenzaprine—Chest pain—Epirubicin—liver cancer	0.000769	0.00292	CcSEcCtD
Cyclobenzaprine—Agitation—Doxorubicin—liver cancer	0.000769	0.00292	CcSEcCtD
Cyclobenzaprine—Anxiety—Epirubicin—liver cancer	0.000767	0.00291	CcSEcCtD
Cyclobenzaprine—Discomfort—Epirubicin—liver cancer	0.00076	0.00289	CcSEcCtD
Cyclobenzaprine—Malaise—Doxorubicin—liver cancer	0.000754	0.00286	CcSEcCtD
Cyclobenzaprine—Dry mouth—Epirubicin—liver cancer	0.000753	0.00286	CcSEcCtD
Cyclobenzaprine—Vertigo—Doxorubicin—liver cancer	0.000751	0.00285	CcSEcCtD
Cyclobenzaprine—Syncope—Doxorubicin—liver cancer	0.00075	0.00285	CcSEcCtD
Cyclobenzaprine—Leukopenia—Doxorubicin—liver cancer	0.000749	0.00284	CcSEcCtD
Cyclobenzaprine—Confusional state—Epirubicin—liver cancer	0.000744	0.00283	CcSEcCtD
Cyclobenzaprine—Palpitations—Doxorubicin—liver cancer	0.000739	0.00281	CcSEcCtD
Cyclobenzaprine—Oedema—Epirubicin—liver cancer	0.000738	0.0028	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Epirubicin—liver cancer	0.000738	0.0028	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Doxorubicin—liver cancer	0.000735	0.00279	CcSEcCtD
Cyclobenzaprine—Shock—Epirubicin—liver cancer	0.000726	0.00276	CcSEcCtD
Cyclobenzaprine—Convulsion—Doxorubicin—liver cancer	0.000725	0.00275	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Epirubicin—liver cancer	0.000722	0.00274	CcSEcCtD
Cyclobenzaprine—Hypertension—Doxorubicin—liver cancer	0.000722	0.00274	CcSEcCtD
Cyclobenzaprine—Tachycardia—Epirubicin—liver cancer	0.00072	0.00273	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Epirubicin—liver cancer	0.000713	0.00271	CcSEcCtD
Cyclobenzaprine—Myalgia—Doxorubicin—liver cancer	0.000712	0.0027	CcSEcCtD
Cyclobenzaprine—Chest pain—Doxorubicin—liver cancer	0.000712	0.0027	CcSEcCtD
Cyclobenzaprine—Anxiety—Doxorubicin—liver cancer	0.00071	0.0027	CcSEcCtD
Cyclobenzaprine—Discomfort—Doxorubicin—liver cancer	0.000703	0.00267	CcSEcCtD
Cyclobenzaprine—Anorexia—Epirubicin—liver cancer	0.000703	0.00267	CcSEcCtD
Cyclobenzaprine—Dry mouth—Doxorubicin—liver cancer	0.000696	0.00265	CcSEcCtD
Cyclobenzaprine—Tamoxifen—ESR1—liver cancer	0.000691	0.157	CrCbGaD
Cyclobenzaprine—Hypotension—Epirubicin—liver cancer	0.000689	0.00262	CcSEcCtD
Cyclobenzaprine—Confusional state—Doxorubicin—liver cancer	0.000688	0.00261	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Doxorubicin—liver cancer	0.000683	0.00259	CcSEcCtD
Cyclobenzaprine—Oedema—Doxorubicin—liver cancer	0.000683	0.00259	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000672	0.00255	CcSEcCtD
Cyclobenzaprine—Shock—Doxorubicin—liver cancer	0.000672	0.00255	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Doxorubicin—liver cancer	0.000668	0.00254	CcSEcCtD
Cyclobenzaprine—Insomnia—Epirubicin—liver cancer	0.000667	0.00253	CcSEcCtD
Cyclobenzaprine—Tachycardia—Doxorubicin—liver cancer	0.000666	0.00253	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Epirubicin—liver cancer	0.000662	0.00252	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Doxorubicin—liver cancer	0.00066	0.00251	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Epirubicin—liver cancer	0.000658	0.0025	CcSEcCtD
Cyclobenzaprine—Somnolence—Epirubicin—liver cancer	0.000656	0.00249	CcSEcCtD
Cyclobenzaprine—Anorexia—Doxorubicin—liver cancer	0.000651	0.00247	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Epirubicin—liver cancer	0.000649	0.00247	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Epirubicin—liver cancer	0.000641	0.00244	CcSEcCtD
Cyclobenzaprine—Hypotension—Doxorubicin—liver cancer	0.000638	0.00242	CcSEcCtD
Cyclobenzaprine—Fatigue—Epirubicin—liver cancer	0.000636	0.00242	CcSEcCtD
Cyclobenzaprine—Constipation—Epirubicin—liver cancer	0.000631	0.0024	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000622	0.00236	CcSEcCtD
Cyclobenzaprine—Nortriptyline—CYP2E1—liver cancer	0.000622	0.141	CrCbGaD
Cyclobenzaprine—Insomnia—Doxorubicin—liver cancer	0.000617	0.00234	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Doxorubicin—liver cancer	0.000613	0.00233	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Doxorubicin—liver cancer	0.000609	0.00231	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Epirubicin—liver cancer	0.000608	0.00231	CcSEcCtD
Cyclobenzaprine—Somnolence—Doxorubicin—liver cancer	0.000607	0.0023	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Epirubicin—liver cancer	0.000603	0.00229	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Doxorubicin—liver cancer	0.000601	0.00228	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Doxorubicin—liver cancer	0.000593	0.00225	CcSEcCtD
Cyclobenzaprine—Fatigue—Doxorubicin—liver cancer	0.000588	0.00224	CcSEcCtD
Cyclobenzaprine—Urticaria—Epirubicin—liver cancer	0.000586	0.00223	CcSEcCtD
Cyclobenzaprine—Constipation—Doxorubicin—liver cancer	0.000584	0.00222	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Epirubicin—liver cancer	0.000583	0.00222	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Doxorubicin—liver cancer	0.000562	0.00214	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP2E1—liver cancer	0.00056	0.127	CrCbGaD
Cyclobenzaprine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000558	0.00212	CcSEcCtD
Cyclobenzaprine—Tamoxifen—CYP1A1—liver cancer	0.000552	0.125	CrCbGaD
Cyclobenzaprine—Orphenadrine—CYP2E1—liver cancer	0.000544	0.123	CrCbGaD
Cyclobenzaprine—Hypersensitivity—Epirubicin—liver cancer	0.000543	0.00206	CcSEcCtD
Cyclobenzaprine—Urticaria—Doxorubicin—liver cancer	0.000542	0.00206	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Doxorubicin—liver cancer	0.00054	0.00205	CcSEcCtD
Cyclobenzaprine—Asthenia—Epirubicin—liver cancer	0.000529	0.00201	CcSEcCtD
Cyclobenzaprine—Pruritus—Epirubicin—liver cancer	0.000522	0.00198	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Epirubicin—liver cancer	0.000505	0.00192	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Doxorubicin—liver cancer	0.000503	0.00191	CcSEcCtD
Cyclobenzaprine—Asthenia—Doxorubicin—liver cancer	0.00049	0.00186	CcSEcCtD
Cyclobenzaprine—Dizziness—Epirubicin—liver cancer	0.000488	0.00185	CcSEcCtD
Cyclobenzaprine—Pruritus—Doxorubicin—liver cancer	0.000483	0.00183	CcSEcCtD
Cyclobenzaprine—Vomiting—Epirubicin—liver cancer	0.000469	0.00178	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Doxorubicin—liver cancer	0.000467	0.00177	CcSEcCtD
Cyclobenzaprine—Rash—Epirubicin—liver cancer	0.000465	0.00177	CcSEcCtD
Cyclobenzaprine—Dermatitis—Epirubicin—liver cancer	0.000465	0.00177	CcSEcCtD
Cyclobenzaprine—Headache—Epirubicin—liver cancer	0.000462	0.00176	CcSEcCtD
Cyclobenzaprine—Dizziness—Doxorubicin—liver cancer	0.000451	0.00171	CcSEcCtD
Cyclobenzaprine—Nausea—Epirubicin—liver cancer	0.000438	0.00166	CcSEcCtD
Cyclobenzaprine—Imipramine—CYP2E1—liver cancer	0.000434	0.0984	CrCbGaD
Cyclobenzaprine—Vomiting—Doxorubicin—liver cancer	0.000434	0.00165	CcSEcCtD
Cyclobenzaprine—Amitriptyline—CYP2E1—liver cancer	0.000431	0.0978	CrCbGaD
Cyclobenzaprine—Rash—Doxorubicin—liver cancer	0.00043	0.00163	CcSEcCtD
Cyclobenzaprine—Dermatitis—Doxorubicin—liver cancer	0.00043	0.00163	CcSEcCtD
Cyclobenzaprine—Headache—Doxorubicin—liver cancer	0.000428	0.00162	CcSEcCtD
Cyclobenzaprine—Nausea—Doxorubicin—liver cancer	0.000405	0.00154	CcSEcCtD
Cyclobenzaprine—Nortriptyline—ALB—liver cancer	0.000341	0.0774	CrCbGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000323	0.00184	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000319	0.00181	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000311	0.00177	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000308	0.00175	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP2E1—liver cancer	0.000307	0.00174	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000303	0.00173	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	0.000303	0.00172	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000302	0.00172	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000302	0.00172	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000296	0.00168	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000295	0.00168	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000287	0.00164	CbGpPWpGaD
Cyclobenzaprine—HTR2A—G alpha (q) signalling events—F2—liver cancer	0.000285	0.00162	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000282	0.0016	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000279	0.00159	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CHN2—liver cancer	0.000273	0.00156	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000271	0.00154	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.00026	0.00148	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000258	0.00147	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000256	0.00146	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.000254	0.00145	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTP1—liver cancer	0.000253	0.00144	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000251	0.00143	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IFT88—liver cancer	0.00025	0.00142	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	0.000249	0.00142	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000246	0.0014	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000239	0.00136	CbGpPWpGaD
Cyclobenzaprine—Amitriptyline—ALB—liver cancer	0.000237	0.0537	CrCbGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTM1—liver cancer	0.000232	0.00132	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000231	0.00131	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000231	0.00131	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	0.000229	0.0013	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000222	0.00126	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP1A1—liver cancer	0.00022	0.00125	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	0.000217	0.00124	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—JUN—liver cancer	0.000215	0.00123	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000215	0.00122	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000215	0.00122	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000214	0.00122	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.000214	0.00122	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000214	0.00121	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—TRIO—liver cancer	0.000212	0.0012	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000211	0.0012	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CCR4—liver cancer	0.000203	0.00115	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000201	0.00114	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000198	0.00113	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000197	0.00112	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000194	0.0011	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—TRIO—liver cancer	0.000192	0.00109	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000191	0.00109	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00019	0.00108	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000188	0.00107	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.000188	0.00107	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000187	0.00106	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CCR4—liver cancer	0.000184	0.00105	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000184	0.00105	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000184	0.00105	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000183	0.00104	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000181	0.00103	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000165	0.000941	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—UGDH—liver cancer	0.000165	0.000938	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000163	0.000928	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—TNF—liver cancer	0.000161	0.000918	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EPT1—liver cancer	0.000155	0.000882	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SHC3—liver cancer	0.000153	0.000872	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000152	0.000865	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.00015	0.000853	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TAT—liver cancer	0.000147	0.000836	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000144	0.00082	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—F2—liver cancer	0.000144	0.000816	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000142	0.000808	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.00014	0.000797	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—UGDH—liver cancer	0.00014	0.000794	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EPT1—liver cancer	0.000131	0.000747	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—IL6—liver cancer	0.00013	0.000741	CbGpPWpGaD
Cyclobenzaprine—HTR2A—G alpha (q) signalling events—PIK3CA—liver cancer	0.000127	0.000724	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TAT—liver cancer	0.000124	0.000708	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000124	0.000704	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000122	0.000696	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FST—liver cancer	0.000119	0.000677	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PRKCE—liver cancer	0.000117	0.000665	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000114	0.000647	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TRIO—liver cancer	0.000114	0.000646	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCR4—liver cancer	0.000109	0.000619	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—UGDH—liver cancer	0.000108	0.000613	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PRKCE—liver cancer	0.000106	0.000604	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000105	0.000599	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CSF2—liver cancer	0.000103	0.000588	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EPT1—liver cancer	0.000101	0.000576	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000101	0.000573	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CPT1B—liver cancer	9.99e-05	0.000568	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GLUL—liver cancer	9.99e-05	0.000568	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NR1H4—liver cancer	9.63e-05	0.000548	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TAT—liver cancer	9.6e-05	0.000546	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTA3—liver cancer	9.47e-05	0.000539	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CSF2—liver cancer	9.39e-05	0.000534	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	9.16e-05	0.000521	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTA4—liver cancer	8.66e-05	0.000493	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ADAM17—liver cancer	8.6e-05	0.000489	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GLUL—liver cancer	8.46e-05	0.000481	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CPT1B—liver cancer	8.46e-05	0.000481	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTA2—liver cancer	8.44e-05	0.00048	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NR1H4—liver cancer	8.16e-05	0.000464	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTA1—liver cancer	8.14e-05	0.000463	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—F2—liver cancer	8.11e-05	0.000461	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PSMA4—liver cancer	8.09e-05	0.00046	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PSMD10—liver cancer	8.09e-05	0.00046	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NAT2—liver cancer	8.05e-05	0.000458	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTA3—liver cancer	8.02e-05	0.000456	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CG—liver cancer	7.76e-05	0.000442	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALDOB—liver cancer	7.72e-05	0.000439	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—F2—liver cancer	7.36e-05	0.000419	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CRABP1—liver cancer	7.36e-05	0.000419	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTA4—liver cancer	7.33e-05	0.000417	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.17e-05	0.000408	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTA2—liver cancer	7.15e-05	0.000407	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CG—liver cancer	7.05e-05	0.000401	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTA1—liver cancer	6.9e-05	0.000392	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CD—liver cancer	6.82e-05	0.000388	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NAT2—liver cancer	6.82e-05	0.000388	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.56e-05	0.000373	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALDOB—liver cancer	6.54e-05	0.000372	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CPT1B—liver cancer	6.53e-05	0.000371	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GLUL—liver cancer	6.53e-05	0.000371	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HPGDS—liver cancer	6.43e-05	0.000366	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NR1H4—liver cancer	6.3e-05	0.000358	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PRKCE—liver cancer	6.27e-05	0.000357	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CRABP1—liver cancer	6.24e-05	0.000355	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CD—liver cancer	6.2e-05	0.000352	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA3—liver cancer	6.19e-05	0.000352	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CB—liver cancer	5.95e-05	0.000338	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF2—liver cancer	5.94e-05	0.000338	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PSMA4—liver cancer	5.74e-05	0.000326	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PSMD10—liver cancer	5.74e-05	0.000326	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA4—liver cancer	5.66e-05	0.000322	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.61e-05	0.000319	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GOT2—liver cancer	5.58e-05	0.000317	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CSF2—liver cancer	5.54e-05	0.000315	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—RAF1—liver cancer	5.53e-05	0.000315	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA2—liver cancer	5.52e-05	0.000314	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—H2AFX—liver cancer	5.46e-05	0.000311	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—IL2—liver cancer	5.46e-05	0.000311	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HPGDS—liver cancer	5.45e-05	0.00031	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.42e-05	0.000308	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CB—liver cancer	5.4e-05	0.000307	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTA1—liver cancer	5.32e-05	0.000303	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NAT2—liver cancer	5.26e-05	0.000299	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP2E1—liver cancer	5.25e-05	0.000298	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALDOB—liver cancer	5.05e-05	0.000287	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2—liver cancer	4.96e-05	0.000282	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TERT—liver cancer	4.94e-05	0.000281	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.94e-05	0.000281	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYCS—liver cancer	4.91e-05	0.000279	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.87e-05	0.000277	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PSMA4—liver cancer	4.86e-05	0.000276	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PSMD10—liver cancer	4.86e-05	0.000276	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GOT1—liver cancer	4.82e-05	0.000274	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GGT1—liver cancer	4.82e-05	0.000274	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CRABP1—liver cancer	4.81e-05	0.000274	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GOT2—liver cancer	4.73e-05	0.000269	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KDR—liver cancer	4.52e-05	0.000257	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK14—liver cancer	4.49e-05	0.000255	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP2E1—liver cancer	4.44e-05	0.000253	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ESR1—liver cancer	4.4e-05	0.000251	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—F2—liver cancer	4.35e-05	0.000248	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTP1—liver cancer	4.33e-05	0.000246	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.3e-05	0.000245	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HMOX1—liver cancer	4.27e-05	0.000243	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HPGDS—liver cancer	4.21e-05	0.000239	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—APC—liver cancer	4.16e-05	0.000237	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CG—liver cancer	4.16e-05	0.000237	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYCS—liver cancer	4.16e-05	0.000237	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GOT1—liver cancer	4.08e-05	0.000232	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GGT1—liver cancer	4.08e-05	0.000232	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTM1—liver cancer	3.98e-05	0.000226	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—BRAF—liver cancer	3.91e-05	0.000223	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP1A1—liver cancer	3.77e-05	0.000214	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PSMA4—liver cancer	3.75e-05	0.000213	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PSMD10—liver cancer	3.75e-05	0.000213	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTP1—liver cancer	3.66e-05	0.000208	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CD—liver cancer	3.66e-05	0.000208	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GOT2—liver cancer	3.65e-05	0.000208	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	3.63e-05	0.000206	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SERPINE1—liver cancer	3.62e-05	0.000206	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HMOX1—liver cancer	3.61e-05	0.000206	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—KRAS—liver cancer	3.58e-05	0.000204	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTHFR—liver cancer	3.51e-05	0.0002	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PPARA—liver cancer	3.45e-05	0.000196	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP2E1—liver cancer	3.43e-05	0.000195	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTM1—liver cancer	3.37e-05	0.000192	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	3.29e-05	0.000187	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RAF1—liver cancer	3.27e-05	0.000186	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYCS—liver cancer	3.21e-05	0.000183	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP1A1—liver cancer	3.19e-05	0.000182	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MTOR—liver cancer	3.19e-05	0.000181	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	3.19e-05	0.000181	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GGT1—liver cancer	3.15e-05	0.000179	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GOT1—liver cancer	3.15e-05	0.000179	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HRAS—liver cancer	3.05e-05	0.000173	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	2.99e-05	0.00017	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTHFR—liver cancer	2.98e-05	0.000169	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	2.96e-05	0.000168	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CG—liver cancer	2.95e-05	0.000168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CASP3—liver cancer	2.93e-05	0.000167	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2—liver cancer	2.93e-05	0.000167	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PPARA—liver cancer	2.92e-05	0.000166	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL6—liver cancer	2.92e-05	0.000166	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—liver cancer	2.86e-05	0.000162	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JUN—liver cancer	2.85e-05	0.000162	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PPARG—liver cancer	2.85e-05	0.000162	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	2.83e-05	0.000161	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTP1—liver cancer	2.83e-05	0.000161	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HMOX1—liver cancer	2.79e-05	0.000159	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MMP9—liver cancer	2.77e-05	0.000158	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	2.76e-05	0.000157	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK8—liver cancer	2.7e-05	0.000153	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—AKT1—liver cancer	2.69e-05	0.000153	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.62e-05	0.000149	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTM1—liver cancer	2.6e-05	0.000148	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CD—liver cancer	2.59e-05	0.000148	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALB—liver cancer	2.56e-05	0.000146	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CG—liver cancer	2.5e-05	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—VEGFA—liver cancer	2.49e-05	0.000142	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT3—liver cancer	2.47e-05	0.00014	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP1A1—liver cancer	2.46e-05	0.00014	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PPARG—liver cancer	2.41e-05	0.000137	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTHFR—liver cancer	2.3e-05	0.000131	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—liver cancer	2.29e-05	0.00013	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFB1—liver cancer	2.29e-05	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CB—liver cancer	2.26e-05	0.000129	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PPARA—liver cancer	2.25e-05	0.000128	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CD—liver cancer	2.2e-05	0.000125	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALB—liver cancer	2.17e-05	0.000123	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KRAS—liver cancer	2.12e-05	0.00012	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	1.94e-05	0.000111	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CG—liver cancer	1.93e-05	0.00011	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CB—liver cancer	1.92e-05	0.000109	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—liver cancer	1.88e-05	0.000107	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PPARG—liver cancer	1.86e-05	0.000106	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HRAS—liver cancer	1.8e-05	0.000102	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL6—liver cancer	1.72e-05	9.8e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CD—liver cancer	1.7e-05	9.65e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALB—liver cancer	1.67e-05	9.53e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKT1—liver cancer	1.59e-05	9.04e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CB—liver cancer	1.48e-05	8.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CA—liver cancer	1.38e-05	7.84e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CA—liver cancer	1.17e-05	6.65e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—AKT1—liver cancer	1.13e-05	6.41e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AKT1—liver cancer	9.54e-06	5.43e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CA—liver cancer	9.01e-06	5.13e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AKT1—liver cancer	7.36e-06	4.19e-05	CbGpPWpGaD
